Buyback Approval and Plan - The board of directors approved a share buyback plan using self-owned funds through centralized bidding on January 23, 2024, with a total fund amount between 200 million yuan and 400 million yuan, and a maximum buyback price of 7 yuan per share [1] Buyback Implementation - The company initiated its first share buyback on January 29, 2024, and completed the buyback by July 21, 2024, acquiring 63.579048 million shares, which is 2.47% of the total share capital at that time. The highest buyback price was 5.00 yuan per share, the lowest was 4.08 yuan, and the average price was 4.72 yuan, with a total expenditure of approximately 299.9241 million yuan [2][3] Use of Funds and Impact - The funds used for the buyback were from the company's own resources and did not significantly impact its daily operations, financial status, or future development. The buyback did not alter the company's control or affect its listing status [3] Shareholder Trading Activity - During the buyback period, company directors, supervisors, and senior management did not trade company shares, except for the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, which planned to increase its stake by 2% to 4% of the total share capital [3] Change in Buyback Share Purpose - The purpose of the repurchased shares was changed from "for equity incentives" to "for cancellation to reduce registered capital" as approved in board meetings held on April 23 and May 2025 [3] Cancellation of Repurchased Shares - The company announced a notification to creditors regarding the cancellation of repurchased shares, with a creditor declaration period from May 24 to July 7, 2025. No creditors requested early debt repayment or guarantees during this period [5] Post-Cancellation Share Capital Changes - After the cancellation of shares, the total share capital will decrease from 2,585,167,996 shares to 2,521,588,948 shares, reflecting a change in ownership percentages among shareholders [6] Shareholder Ownership Changes - Following the cancellation, the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, maintained its shareholding at 594,209,740 shares, increasing its ownership percentage from 22.99% to 23.56% [6]

Summary of Key Points Core Viewpoint - The company, Hefei Qizhong Technology Co., Ltd., has announced a share repurchase plan to enhance shareholder value and implement an employee stock ownership plan, with a total expected repurchase amount between 75 million and 150 million RMB [1]. Group 1: Share Repurchase Plan - The share repurchase plan was first disclosed on June 19, 2025, and will be implemented from June 18, 2025, to June 17, 2026 [1]. - The repurchase price will not exceed 16.61 RMB per share, and the total repurchase amount will be no less than 75 million RMB [1]. - The company has already repurchased 550,343 shares, which accounts for 0.05% of the total share capital of 1,189,037,288 shares [1]. Group 2: Progress of Share Repurchase - The highest repurchase price recorded was 11.27 RMB per share, while the lowest was 11.10 RMB per share, with a total expenditure of 6,174,000.68 RMB (excluding transaction fees) [1][2]. - The company will adhere to relevant laws and regulations during the repurchase process and will disclose information regarding the progress of the repurchase in a timely manner [2][3].

Group 1 - The company has approved a share repurchase plan using its own funds through centralized bidding, with a maximum repurchase price of RMB 31.00 per share and a total repurchase amount between RMB 1 billion and RMB 1.2 billion, to be completed within 12 months [1] - As of June 30, 2025, the company has repurchased 15,315,910 shares, accounting for 0.70% of the total share capital, with a total expenditure of RMB 252,957,449.12, at prices ranging from RMB 13.64 to RMB 24.91 per share [2] - The company has obtained a loan commitment letter from China Bank, which allows for financing support for the share repurchase, with a loan amount not exceeding RMB 300 million [3] Group 2 - The repurchase plan's implementation period has been extended by 9 months, and the funding sources have been adjusted to include both self-owned and self-raised funds, while other details remain unchanged [2] - The company will adhere to relevant laws and regulations during the repurchase period and will disclose progress to investors [3]

证券代码:002048 证券简称:宁波华翔 公告编号:2025-055 董事会公告 宁波华翔电子股份有限公司 （结果取小数点后六位）。除权除息参考价=股权登记日收盘价-0.4683672 元/股。 本次权益分派股权登记日为：2025 年 7 月 15 日，除权除息日为：2025 年 7 月 16 日 。 具 体 内 容 详 见 公 司 于 2025 年 7 月 9 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《2024 年年度权益分派实施公告》（公告 编号：2025-054）。 本公司全体董事、监事、高级管理人员保证公告内容真实、准确和完整，并对 公告中的虚假记载、误导性陈述或者重大遗漏承担责任。 特别提示： 一、回购股份的基本情况 宁波华翔电子股份有限公司（以下简称"公司"）于 2024 年 11 月 13 日、2024 年 12 月 4 日分别召开第八届董事会第十三次会议、2024 年第一次临时股东大会， 审议通过了《关于回购公司股份方案的议案》，同意公司使用自有资金和专项贷款 资金以集中竞价交易方式回购公司股份，用于注销并减少公司注册资本。本次回购 资金总额为不 ...

Group 1 - The company has approved a share repurchase plan with a total fund range of 151 million to 300 million RMB, with a maximum repurchase price set at 19.00 RMB per share [1] - Due to the implementation of the 2024 annual profit distribution, the maximum repurchase price has been adjusted to 18.81 RMB per share, effective from July 9, 2025 [2] - The adjustment in repurchase price is a result of the cash dividend distribution, which reduces the price by the calculated cash dividend per share of 0.1946984 RMB [2] Group 2 - The total cash dividend amount for the company is 231,775,419.60 RMB, based on a distribution ratio of 0.2 RMB per share [2] - The total share capital remains unchanged post-distribution, but the cash dividend per share will decrease due to the exclusion of repurchased shares from the distribution [2] - The company will continue to disclose information regarding the progress of the share repurchase [3]

本报记者 陈红 今年以来，A股上市公司回购股份热度不减。近期，多行业上市公司密集推出回购股份计划，且普遍将员工激励作为核心 方向，引发市场广泛关注。 举例来看，7月7日晚间，苏州富士莱医药股份有限公司发布公告称，公司拟使用自有资金2000万元至4000万元回购公司股 份，用于实施股权激励计划或员工持股计划。本次回购股份的价格不超过40元/股，按回购价格上限和回购金额上限测算，预 计回购股份数量约100万股，占公司总股本的1.09%。 7月5日，浙江新中港热电股份有限公司发布回购报告书，计划以自有资金回购公司股份，资金总额不低于4000万元且不超 过8000万元，回购股份同样用于员工持股计划或股权激励。 工信部信息通信经济专家委员会委员盘和林向《证券日报》记者表示，上市公司回购股份，是对自身价值的深度认可，认 为当前股价未能反映公司真实价值。多家公司也在公告中明确，回购是基于对未来发展的信心和价值认可，既为增强投资者信 心，也为健全长效激励机制，推动企业持续健康发展。 梳理相关公告可以发现，回购股份用于员工持股计划或股权激励（统称"员工激励"）的占比较高。南开大学金融学教授田 利辉向《证券日报》记者表示，回购与 ...

证券代码：688208 证券简称：道通科技 公告编号：2025-055 转债代码：118013 转债简称：道通转债 一、 回购审批情况和回购方案内容 第四届董事会第十九次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》，同意公司使用自有资金通过集中竞价交易方式回购公司已发行的 人民币普通股（A 股），本次回购的股份拟用于维护公司价值及股东权益。公司拟 用于本次回购的资金总额不低于人民币 1 亿元（含），不超过人民币 2 亿元（含）， 回购价格为不超过人民币 63.83 元/股（含）。本次回购实施期限为自董事会审议通 过本次回购股份方案之日起 3 个月内。具体内容详见公司分别于 2025 年 4 月 9 日和 2025 年 4 月 10 日在上海证券交易所网站（www.sse.com.cn）披露的《关于 以集中竞价交易方式回购公司股份方案的公告》 （公告编号：2025-028）和《关于 以集中竞价交易方式回购公司股份的回购报告书》（公告编号：2025-029）。 因实施 2024 年年度权益分派，公司以集中竞价交易方式回购股份的价格上限 由不超过人民币 63.83 元/股（含）调整为不超过人民 ...

重要内容提示： 证券代码：600927 证券简称：永安期货 公告编号：2025-041 永安期货股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 ） 股票连续 2 个交易日（2025 年 7 月 7 日、2025 年 7 月 8 日）内 日收盘价格涨幅偏离值累计超过 20%，根据《上海证券交易所交 易规则》有关规定，属于股票交易异常波动情况。 公告日，不存在应披露而未披露的重大信息。 审慎投资。 一、股票交易异常波动的具体情况 公司股票于 2025 年 7 月 7 日、2025 年 7 月 8 日连续 2 个交 易日内日收盘价格涨幅偏离值累计超过 20%，根据《上海证券交 易所交易规则》的有关规定，属于股票交易异常波动情况。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，近期公司经营活动正常，外部环境未发生重大 变化。截至 2024 年年末，归属于上市公司股东的所有者权益为 亿元，同比下降 8.76%；归属于上市公司股东的净利润 5.75 亿元， 同比下降 21.07%。20 ...

香港金融管理局总裁余伟文：8月底将推出人民币回购优化措施 智通财经7月8日电，香港金融管理局总裁余伟文7月8日在"债券通周年论坛2025"上表示，目前债券 通"北向通"参与者可使用合资格在岸债券作为抵押品，在香港进行人民币回购业务，未来将进一步拓展 人民币回购业务，支持再质押及跨境货币回购，结算与清算等操作安排将相应优化，预计将于8月底实 施。 ...

证券代码：002026 证券简称：山东威达 公告编号：2025-053 山东威达机械股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示 股，占注销前公司总股本的 1.16%，实际回购注销金额为人民币 59,987,055.00 元。本次注销 完成后，公司总股本由 445,703,339 股减少至 440,531,939 股。 已于 2025 年 7 月 7 日办理完成。 公司于 2025 年 4 月 19 日召开第十届董事会第二次会议、于 2025 年 5 月 20 日召开 2024 年度股东大会，审议通过了《关于回购公司股份方案的议案》，同意公司使用自有资金以集中 竞价交易方式回购公司已发行的部分人民币普通股 A 股，用于回购的资金总额不低于人民币 元/股（含本数），回购股份将用于注销并减少公司注册资本，回购股份的期限自股东大会审 议通过回购股份方案之日起 12 个月内。公司已就本次回购股份事项依法履行了通知债权人的 程序。详细内容请见公司于 2025 年 4 月 22 日、2025 年 5 月 27 日刊登在《中国证券报》 《证 券时报 ...